Bio-Bridge Science

Bio-Bridge Science is a biotechnology company focused on the development and commercialization of vaccines for infectious diseases and certain types of cancer. The company's lead program is a prophylactic HIV-1 vaccine (GE-02-01) based on a DNA vaccine platform, which has reached Phase 1 clinical trials in China. Additionally, the company is developing a therapeutic vaccine for Human Papillomavirus (HPV) and a vaccine for colon cancer. Bio-Bridge Science also engages in the production and sale of laboratory materials, including fetal bovine serum, through its subsidiaries in Beijing. While the company has historically been publicly traded, it has faced significant operational and financial challenges in recent years.